Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NASH Clear all
Completed Phase 2 Interventional Results available

Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)

NCT01694849
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis (NASH)
Interventions
GFT505 80mg, GFT505 120mg, Placebo
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 75 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
19
States / cities
Fresno, California • La Jolla, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

NCT03987451
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis
Interventions
Semaglutide, Placebo (semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
24
States / cities
Chandler, Arizona • Peoria, Arizona • Coronado, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 20, 2026, 4:48 AM EDT
Active, not recruiting Not applicable Interventional

Weight, Energy, Lipids, and the Liver (WELL) Study

NCT05199948
View directory record Official record
Conditions
Nonalcoholic Fatty Liver
Interventions
Soybean Oil Foods, Palm Oil Foods
Other
Lead sponsor
Ohio State University
Other
Eligibility
22 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Active, not recruiting No phase listed Observational

Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis

NCT05507151
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Endoscopic Sleeve Gastroplasty
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Timeline
2022 – 2026
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

NCT04006145
View directory record Official record
Conditions
NAFLD, NASH
Interventions
Elobixibat, Placebo oral tablet
Drug
Lead sponsor
Albireo
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Canoga Park, California • Rialto, California • Colorado Springs, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Enrolling by invitation Not applicable Interventional

Improving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED

NCT06944353
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Steatosis of Liver, Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
STIRRED
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
4,704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Vigabatrin and Insulin Sensitivity

NCT04321395
View directory record Official record
Conditions
NAFLD, Obesity
Interventions
Vigabatrin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional Results available

Study of INT-747 in Patients With Diabetes and Presumed NAFLD

NCT00501592
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Fatty Liver
Interventions
INT-747, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 20, 2026, 4:48 AM EDT
Completed No phase listed Observational

Ultrasound Quantification of Liver Fat

NCT04523584
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound Imaging
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
16 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed No phase listed Observational

Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease

NCT05669677
View directory record Official record
Conditions
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD, NASH
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)

NCT04267393
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
BMS-986263, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
21 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Chandler, Arizona • Phoenix, Arizona • La Jolla, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional

Feasibility of VIIT in Adults With NASH

NCT03861819
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Liver Diseases
Interventions
Vigorous-intensity interval training (VIIT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 59 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 20, 2026, 4:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571
View directory record Official record
Conditions
NASH/MASH, NAFLD/MASLD
Interventions
Efruxifermin, Placebo
Drug
Lead sponsor
Akero Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
139
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05463796
View directory record Official record
Conditions
Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Interventions
Samples
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Intrahepatic Lipids With Exercise

NCT02181270
View directory record Official record
Conditions
Obese
Interventions
high intensity exercise, continuous moderate exercise
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Phase 2 Interventional

Saroglitazar Magnesium for the Treatment of Nonalcoholic Steatohepatitis With Fibrosis

NCT05011305
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Fibrosis
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
101
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High Fructose Corn Syrup

NCT02018237
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Obesity
Interventions
High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 20, 2026, 4:48 AM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 20, 2026, 4:48 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease

NCT04766476
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
BMS-963272, Placebo matching BMS-963272
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
19
States / cities
Cullman, Alabama • Chandler, Arizona • Tucson, Arizona + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 20, 2026, 4:48 AM EDT
Completed No phase listed Observational

Bariatric Surgery-Induced Shift in Gut Microbiome and NAFLD

NCT04263376
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Type 2, NAFLD
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 20, 2026, 4:48 AM EDT
Withdrawn No phase listed Observational

Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children

NCT00677183
View directory record Official record
Conditions
Non-Alcoholic Steatohepatitis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Oct 20, 2026, 4:48 AM EDT
Recruiting No phase listed Observational

Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease

NCT05728697
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Interventions
Endoscopic ultrasound shear wave elastography
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 4:48 AM EDT